drugset / Trial / NCT05777993
A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to provide continued access to mitapivat for participants who completed an Agios-sponsored mitapivat study (antecedent) and do not have commercial access to mitapivat.
Timeline
- Start
- 2023-07-06
- Primary completion
- 2029-08
- Completion
- 2029-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitapivat | Small molecule | 5 mg | Oral |
| Subject | Mitapivat | Small molecule | 20 mg | Oral |
| Subject | Mitapivat | Small molecule | 50 mg | Oral |